Rani Therapeutics Files 8-K on Shareholder Votes

TL;DR

Rani Therapeutics filed an 8-K about shareholder votes. Keep an eye on what they voted on.

AI Summary

Rani Therapeutics Holdings, Inc. filed an 8-K on May 30, 2024, reporting on matters submitted to a vote of security holders as of May 29, 2024. The filing details the company's corporate information, including its address in San Jose, California, and its principal executive offices.

Why It Matters

This filing indicates that Rani Therapeutics is engaging with its shareholders on important corporate decisions, which could impact the company's direction and shareholder rights.

Risk Assessment

Risk Level: low — This is a routine corporate filing regarding shareholder votes and does not appear to contain significant new financial or operational risks.

Key Players & Entities

• Rani Therapeutics Holdings, Inc. (company) — Registrant
• May 29, 2024 (date) — Date of earliest event reported
• May 30, 2024 (date) — Date of report
• San Jose, California (location) — Principal executive offices location

FAQ

Key Financial Figures

• $0.0001 — tered Class A common stock, par value $0.0001 per share RANI The Nasdaq Stock Mar

Filing Documents

• rani-20240529.htm (8-K) — 53KB
• 0000950170-24-066552.txt ( ) — 168KB
• rani-20240529.xsd (EX-101.SCH) — 25KB
• rani-20240529_htm.xml (XML) — 5KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On May 29, 2024, Rani Therapeutics Holdings, Inc. (the "Company") held its annual meeting of stockholders ("Annual Meeting"). As of April 2, 2024, the record date for the Annual Meeting, there were 26,294,303 shares of Class A common stock outstanding and entitled to vote and 24,116,444 shares of Class B common stock outstanding and entitled to vote at the Annual Meeting. Holders of the Company's Class A common stock are entitled to one vote per share and holders of the Company's Class B common stock are entitled to ten votes per share. Holders of Class A common stock and Class B common stock voted together as a single class on all matters submitted to a vote of stockholders at the Annual Meeting. The following is a summary of the matters voted on at the Annual Meeting based on the report of the voting results by the inspector of election. The Company's Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 17, 2024 contains a description of the following proposals considered at the Annual Meeting, each of which were approved by the Company's stockholders at the Annual Meeting as set forth below: 1. The Company's stockholders elected by a majority of votes cast the director nominees below, to hold office until the 2025 annual meeting of stockholders or until their successors are duly elected and qualified, as follows: For Withheld Broker Non-Votes Talat Imran 225,732,680 22,627 6,341,402 Mir Imran 225,408,629 346,678 6,341,402 Dennis Ausiello 225,419,605 335,702 6,341,402 Jean-Luc Butel 225,406,754 348,553 6,341,402 Laureen DeBuono 225,390,033 365,274 6,341,402 Andrew Farquharson 225,730,127 25,180 6,341,402 Malik Nanavaty 225,387,085 368,222 6,341,402 Lisa Rometty 225,737,394 17,913 6,341,402 2. The Company's stockholders ratified the appointment of Ernst & Young, LLP as the Compa

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Rani Therapeutics Holdings, Inc. Date: May 30, 2024 By: /s/ Svai Sanford Svai Sanford Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR